AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04702425
Drug: VOB560
RxNorm normalized name: VOB560
DrugBank: S65487 (DB17556)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Powder for concentrate for solution for infusion
Trial: NCT04702425
Drug: MIK665
RxNorm normalized name: MIK665
DrugBank: S64315 (DB17559)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concentrate for solution for infusion
Trial: NCT04654078
Drug: IN-C004 with water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One time dose of IN-C004 taken with water
Trial: NCT04654078
Drug: IN-C004 without water
RxNorm normalized name: ethanol
DrugBank: Water (DB09145)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One time dose of IN-C004 taken without water
Trial: NCT04654078
Drug: K-CAB tab. with water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One time dose of K-CAB tab. taken with water
Trial: NCT06261359
Drug: CEND-1
RxNorm normalized name: Cendakimab
DrugBank: Cendakimab (DB18427)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEND-1 will be provided as concentrate for solution to be administered via IV injection.
Trial: NCT06261359
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine will be provided as solution to be administered via IV infusion.
Trial: NCT06261359
Drug: Nab paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nab-paclitaxel will be provided as solution to be administered via IV infusion.
Trial: NCT05157139
Drug: Oral Capsule
RxNorm normalized name: Oral Capsule
DrugBank: Citric acid (DB04272)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Capsule of vanillin \& wheat germ oil
Trial: NCT05829655
Drug: Drug D (Blinded Drug)
RxNorm normalized name: Lenti-d drug product
DrugBank: Elivaldogene tavalentivec (DB19095)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a double-blinded oral study medication as part of their daily sessions and will provide feedback regarding the effects of the medication on various measures. Though the study medications are FDA approved, they are being used here for a non-FDA approved purpose (though the FDA has provided permission to use these drugs in this study).
Trial: NCT05829655
Drug: Suvorexant (20mg/day)
RxNorm normalized name: Suvorexant
DrugBank: Suvorexant (DB09034)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Double blind administration of suvorexant once per day during residential stay until discharge.
Trial: NCT06450132
Drug: Atropine Ophthalmic
RxNorm normalized name: atropine ophthalmic
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.05% atropine ophthalmic solution
Trial: NCT05974449
Drug: Vaginal Lactobacillus capsules
RxNorm normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This product is a micro-ecological preparation made from live Lactobacillus and is used for the treatment of vaginosis caused by disorders of the flora.
Trial: NCT06140537
Drug: Dapagliflozin 10mg Tab
RxNorm normalized name: DAPAGLIFLOZIN 10MG TAB
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dapagliflozin 10mg orally daily
Trial: NCT05252923
Drug: Sulodexide
RxNorm normalized name: sulodexide
DrugBank: Sulodexide (DB06271)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulodexide 250 LSU 1 oral capsule twice daily for 8 weeks
Trial: NCT04965038
Drug: Alteplase
RxNorm normalized name: Alteplase
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous thrombolysis with alteplase within 4.5 hours of symptom onset
Trial: NCT05314933
Drug: 2-Deoxyglucose
RxNorm normalized name: 2-DEOXYGLUCOSE
DrugBank: 2-deoxyglucose (DB08831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal administration
Trial: NCT00002020
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05099159
Drug: Elinzanetant (BAY3427080)
RxNorm normalized name: Elinzanetant
DrugBank: Elinzanetant (DB18968)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg elinzanetant orally once daily
Trial: NCT06221748
Drug: Disitamab Vedotin Injection
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Disitamab vedotin (DB17208)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Phase II and III study ：2.5mg/kg, intravenous infusion，D1, every 2 weeks
Trial: NCT06221748
Drug: Cadonilimab Injection
RxNorm normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase II and III study ：6.0mg/kg, intravenous infusion，D1, every 2 weeks.
Trial: NCT06221748
Drug: Paclitaxel Injection
RxNorm normalized name: paclitaxel Injection
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Phase II and III study ：Calculate dosage based on body surface are,160mg/m2,intravenous infusion，D1,D8 every 3 weeks
Trial: NCT05503888
Drug: Almonertinib combined with SHR-1701
RxNorm normalized name: miconazole
DrugBank: Almonertinib (DB16640)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Phase Ⅰb/Phase Ⅱ：~SHR-1701: injection, intravenous infusion~Almonertinib: tablets, oral
Trial: NCT05503888
Drug: Almonertinib
RxNorm normalized name: Almonertinib
DrugBank: Almonertinib (DB16640)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase Ⅱ:~Almonertinib: tablets, oral
Trial: NCT05934331
Drug: LM302+Toripalimab
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LM-302 in combination with Toripalimab.
Trial: NCT05040360
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT06158113
Drug: Baricitinib 4 milligram Oral Tablet
RxNorm normalized name: baricitinib 4 MG
DrugBank: Baricitinib (DB11817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 4 milligrams once daily
Trial: NCT06304779
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine group receive a loading dose of 1.5 mg/kg 2% lidocaine at anesthesia induction, followed by continuous intravenous infusion at 1.5 mg/kg/h until 24 hours postoperatively and Control group receive an equivalent volume of normal saline at anesthesia induction and throughout the perioperative period until 24 hours postoperatively.~Both groups will receive the same anesthesia and postoperative analgesia protocols, lung-protective ventilation strategy, and fluid, transfusion, and warming strategies. The only difference is the intervention during surgery, with the lidocaine group receiving continuous intravenous lidocaine.
Trial: NCT04088591
Drug: Dextrose in Water
RxNorm normalized name: dextrose in water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 ml of 5% dextrose in water every 6 hours for a total duration of 96 hours
Trial: NCT04768400
Drug: Arm I (MEP)
RxNorm normalized name: IOBENGUANE I 123
DrugBank: Iobenguane (DB06704)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm I (MEP): Motor evoked potential will be measured in various degree of the neuromuscular blockade.
Trial: NCT05614648
Drug: Clonidine Micropellets
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.975 mg clonidine hydrochloride as 3 micropellets administered in one injection
Trial: NCT06383468
Drug: AK120
RxNorm normalized name: Abiraterone acetate
DrugBank: Abiraterone (DB05812)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 300mg Q2W subcutaneous injection thereafter until week 50.
Trial: NCT00051584
Drug: SGN-15 (cBR96-Doxorubicin Immunoconjugate)
RxNorm normalized name: Moab, chimeric, SGN-30, to CD30 antigen
DrugBank: SGN-15 (DB05818)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05446571
Drug: Letermovir
RxNorm normalized name: Letermovir
DrugBank: Letermovir (DB12070)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Maternal daily administration of 240 milligrams of letermovir (1x240 mg-tablets) up-until delivery or TOP Placebo of Valaciclovir ; daily administration of 8 grams of valaciclovir (2 g (4 x500 mg-tablets) every 6 hours) up-until delivery or TOP
Trial: NCT05446571
Drug: Valacyclovir
RxNorm normalized name: Valacyclovir
DrugBank: Valaciclovir (DB00577)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maternal daily administration of 8 grams of valaciclovir (2 g (4 x500 mg-tablets) every 6 hours) up-until delivery or TOP Placebo of letermovir : (1x240 mg-tablets) up-until delivery or TOP
Trial: NCT00051584
Drug: Gemzar (Gemcitabine)
RxNorm normalized name: gemcitabine Injection [Gemzar]
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT05541445
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The subjects first receive induction therapy with pembrolizumab combined with chemotherapy for 6 weeks, and then receive sequential therapy with pembrolizumab combined with concurrent chemoradiotherapy for 6 weeks, and receive surgical treatment within 4-8 weeks after neoadjuvant therapy. For patients whose postoperative pathology is confirmed as PCR (pathological complete response), the patients will be observed with long-time follow-up; If the postoperative pathology is confirmed as non-PCR, pembrolizumab will be administrated until 1 year or disease progression or intolerable toxicity.
Trial: NCT00002112
Drug: Nystatin
RxNorm normalized name: Nystatin
DrugBank: Nystatin (DB00646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002112
Drug: Fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05521789
Drug: ESB Thoracic
RxNorm normalized name: Esbriet
DrugBank: Pirfenidone (DB04951)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Erector spinae thoracic block with bupivacaine
Trial: NCT06423846
Drug: sevoflurane group
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For patients in the SEVO group, general anesthesia was induced with propofol 2 mg/kg, fentanyl 1 ug/kg and then maintained with sevoflurane in air and oxygen, dexmedetomidine 1 ug/kg/hour.
Trial: NCT00690911
Drug: adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 40mg dose subcutaneously using sterile technique. The site research staff will instruct and supervise subjects or a designee or nurse on proper injection technique during site visit evaluations. Subjects or a reliable designee will administer injectable study drug at home in between site visit evaluations.
Trial: NCT04840550
Drug: Lansoprazole 15 mg
RxNorm normalized name: lansoprazole 15 MG
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lansoprazole 15 mg tablets will be orally administered once a day, with NSAIDs, for up to 6 months.
Trial: NCT04840550
Drug: Tegoprazan 25 mg
RxNorm normalized name: Tegoprazan
DrugBank: Tegoprazan (DB16690)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tegoprazan 25 mg tablets will be orally administered once a day, with NSAIDs, for up to 6 months.
Trial: NCT04648189
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: A single dose of cetuximab, 400mg/m2, will be administered 72 to 48 hours prior to surgery
Trial: NCT05946005
Drug: honey
RxNorm normalized name: Honey
DrugBank: Honey (DB14242)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tresno Joyo honey applied routinely to the wound two times a day for 14 days. BPOM (National Agency of Drug and Food Control) number: MD252109001219
Trial: NCT05946005
Drug: lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dolones cream applied routinely to the wound two times a day for 14 days. BPOM (National Agency of Drug and Food Control) number: DKL0922246629AI
Trial: NCT05946005
Drug: povidone-iodine
RxNorm normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betadine cream applied routinely to the wound two times a day for 14 days. BPOM (National Agency of Drug and Food Control) number: PKD20501710037
Trial: NCT05923190
Drug: Enfortumab vedotin
RxNorm normalized name: ENFORTUMAB VEDOTIN
DrugBank: Enfortumab vedotin (DB13007)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: EV will be administered at standard dose of 1.25 mg/kg IV on days 1 and 8 with pembrolizumab 200 mg IV on day 1 of a 21-day cycle for 6 cycles
Trial: NCT05923190
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab will be administered on day 1 of a 21-day cycle
Trial: NCT05178862
Drug: SCY-078
RxNorm normalized name: SCY-635
DrugBank: SCY-635 (DB12451)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ibrexafungerp (SCY-078) as step-down therapy.
Trial: NCT05178862
Drug: Fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral fluconazole (SCY-078) as step-down therapy.
Trial: NCT04629027
Drug: Immune checkpoint inhibitor
RxNorm normalized name: Anti-tim3 checkpoint inhibitor mbg453
DrugBank: Sabatolimab (DB16322)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the patients receive necessary treatment without special intervention
Trial: NCT05849519
Drug: Coenzyme I for Injection + conventional treatment
RxNorm normalized name: iobenguane I-131 Injection
DrugBank: Iobenguane (DB06704)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intervention group used Coenzyme I for injection and conventional treatment for 7 consecutive days
Trial: NCT04377152
Drug: 68Gallium-PSMA-11
RxNorm normalized name: Gallium Ga 68 PSMA-11
DrugBank: Gallium nitrate (DB05260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PSMA-11 Ga 68 Injection is a positron emitting radiopharmaceutical containing radioactive 68Ga-labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC (PSMA-11), which is used for diagnostic purposes in conjunction with Positron Emission Tomography (PET).
Trial: NCT05667220
Drug: Sitagliptin
RxNorm normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sitagliptin monotherapy group (Group A): 20 eligible patients were planned to be included and given Sitagliptin 100 mg Qd orally; the treatment period was 1 week.
Trial: NCT05667220
Drug: Sitagliptin combined with Beidougen capsule
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sitagliptin combined with Beidougen capsule treatment group (Group B): 20 eligible patients were planned to be included and given sitagliptin 100mg Qd orally combined with Beidougen capsule 60mg Tid orally. The treatment period was 1 week.
Trial: NCT05954767
Drug: IS-001
RxNorm normalized name: IS-5MN
DrugBank: Isosorbide mononitrate (DB01020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV injection of IS-001 drug substance with near infrared (NIR) imaging
Trial: NCT04826016
Drug: Eribulin
RxNorm normalized name: Eribulin
DrugBank: Eribulin (DB08871)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Eribulin: 1.23 mg/m2 (equivalent to 1.4 mg/m2 eribulin mesylate). Intravenous administration on day 1 and 8 of each 21-day cycle (+/- 1 day) (Phase Ib ARM A and Phase II ARM A ) or on day 1, 8 and 15 of each 28-day cycle (Phase Ib ARM B and Phase 2 ARM B) (+/- 1 day).
Trial: NCT04826016
Drug: Nab paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nab-paclitaxel: 100 mg/m2. Intravenous administration on day 1 and 8 of each 21-day cycle (+/- 1 day) (Phase Ib ARM A and Phase II ARM A) or on day 1, 8 and 15 of each 28-day cycle (Phase Ib ARM B and Phase 2 ARM B) (+/- 1 day).
Trial: NCT05126628
Drug: Proxalutamide
RxNorm normalized name: Proxalutamide
DrugBank: Proxalutamide (DB16065)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proxalutamide 300mg q.d.(3 tablets of 100mg each) for 14 days.
Trial: NCT05188495
Drug: trastuzumab(Henlius®) combined with Pertuzumab(Perjeta®) and Chemotherapy
RxNorm normalized name: hyaluronidase / pertuzumab / trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: trastuzumab(Henlius®) combined with Pertuzumab(Perjeta®) and Chemotherapy； TPC:treatment of physician's choice,include taxanes，Gemcitabine, capecitabine, vinorelbine
Trial: NCT00002153
Drug: A-007
RxNorm normalized name: camphor 0.007 MG/MG
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05940532
Drug: Sugemalimab and Chemotherapy
RxNorm normalized name: cytarabine and daunorubicin
DrugBank: Sugemalimab (DB16641)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy: Paclitaxel 175mg/m2 D1, Carboplatin AUC=5 or DDP 75mg/m2 D1 for NSCLC; Pemetrexed 500mg/m2 D1, Carboplatin AUC=5 or DDP 75mg/m2 D1 for non-squamous NSCLC; intravenous infusion every 3 weeks, for up to four cycles.~Sugemalimab: 1200 mg by intravenous infusion every 3 weeks, for up to 2 years.
Trial: NCT05408026
Drug: Daratumumab
RxNorm normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Daratumumab (and hyaluronidase) will be given over 3-5 minutes subcutaneously (under the skin) in the clinic at alternating left/right abdominal sites. Patient will take dexamethasone orally (by mouth) either before coming to clinic or in clinic, before other medications.~Only for the first cycle, patient will receive on Day 1 daratumumab (which is mixed with a compound called hyaluronidase) and dexamethasone, 1 day before patient start the other 2 medications.
Trial: NCT05408026
Drug: Pomalidomide
RxNorm normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: On day 2 of cycle 1, patient will start the other medications and will therefore receive bortezomib administered subcutaneously (SC) over 3-5 minutes and dexamethasone given orally (by mouth), either before coming to clinic or in clinic, before bortezomib. Patient will also start pomalidomide on the same day, which patient will take that evening at home and every evening for 21 days.
Trial: NCT06088264
Drug: BMS-986322
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Specified dose on specified days.
Trial: NCT06432166
Drug: 2-hydroxybenzylamine acetate
RxNorm normalized name: hydroxybenzopyridine
DrugBank: Benzylamine (DB02464)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-hydroxybenzylamine acetate (2-HOBA) is taken three times per day for 16 weeks
Trial: NCT04628988
Drug: CC-90011
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule
Trial: NCT04628988
Drug: Abiraterone
RxNorm normalized name: ABIRATERONE
DrugBank: Abiraterone (DB05812)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT04628988
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT04332796
Drug: Chorhexidine scrub
RxNorm normalized name: chlorhexidine Medicated Liquid Soap [Scrub-Stat]
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chorhexidine scrub was given to patients for 4 weeks
Trial: NCT05968651
Drug: Oxytocin nasal spray
RxNorm normalized name: oxytocin Nasal Spray
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single acute administration of 24 international units (IU) oxytocin
Trial: NCT04730050
Drug: TT-01025-CL
RxNorm normalized name: TT 173
DrugBank: TT 173 (DB17717)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet
Trial: NCT06580236
Drug: Botulinum neurotoxin type A
RxNorm normalized name: Botulinum A neurotoxin
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Infusion
Trial: NCT05008666
Drug: Sintilimab
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. To evaluate the short-term objective efficacy of sintilimab Sequential combined with chidamide and azacitidine in the treatment of ENKTL-HLH patients.~2. To evaluate the long-term efficacy and safety of sintilimab Sequential combined with chidamide and azacitidine in the treatment of ENKTL-HLH patients.~3. Exploring biomarkers that may have predictive effects.
Trial: NCT05008666
Drug: Chidamide
RxNorm normalized name: Chidamide
DrugBank: Tucidinostat (DB06334)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: 1. To evaluate the short-term objective efficacy of sintilimab Sequential combined with chidamide and azacitidine in the treatment of ENKTL-HLH patients.~2. To evaluate the long-term efficacy and safety of sintilimab Sequential combined with chidamide and azacitidine in the treatment of ENKTL-HLH patients.~3. Exploring biomarkers that may have predictive effects.
Trial: NCT05008666
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1. To evaluate the short-term objective efficacy of sintilimab Sequential combined with chidamide and azacitidine in the treatment of ENKTL-HLH patients.~2. To evaluate the long-term efficacy and safety of sintilimab Sequential combined with chidamide and azacitidine in the treatment of ENKTL-HLH patients.~3. Exploring biomarkers that may have predictive effects.
Trial: NCT05008666
Drug: L-DEP
RxNorm normalized name: L-Deprenalin
DrugBank: L-deprenyl-D2 C-11 (DB12650)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-DEP
Trial: NCT05293704
Drug: Mizoribine
RxNorm normalized name: Mizoribine
DrugBank: Mizoribine (DB12617)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally administered at 3-4 mg/kg/d, once every 12 hours; When body weight ≤50 kg, each dose of 75 mg; Weight \& gt At 50 kg, the dosage was 100 mg each time.
Trial: NCT05965687
Drug: Intravenous thrombolysis(rt-PA)
RxNorm normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% dose of rt-PA (0.9 mg/kg) is given as bolus and the rest given as an infusion over the remaining 1 hour. Maximum dose 90mg.